Skip to main content

Table 5 Univariate analysis of factors predictive of progression-free and overall survival

From: Baseline total metabolic tumor volume combined with international peripheral T-cell lymphoma project may improve prognostic stratification for patients with peripheral T-cell lymphoma (PTCL)

Variable No. of patients (n = 84) Progression-free survival Overall survival
B SE Wald HR (95% CI) P value* B SE Wald HR (95% CI) P value*
Sex, F/M 30/54 0.334 0.315 1.124 1.396 (0.753–2.588) 0.289 0.374 0.323 1.342 1.454 (0.772–2.738) 0.247
Age, ≤ 60/> 60 43/41 0.513 0.304 2.841 1.670 (0.920–3.032) 0.092 0.576 0.305 3.564 1.779 (0.978–3.236) 0.059
LDH level, normal/elevated 38/46 0.679 0.310 4.790 1.972 (1.073–3.621) 0.029 0.800 0.317 6.389 2.226 (1.197–4.141) 0.011
B symptoms, no/yes 33/51 0.861 0.334 6.662 2.366 (1.230–4.550) 0.010 0.840 0.341 6.072 2.317 (1.188–4.520) 0.014
ECOG PS, 0–1/≥ 2 57/27 1.055 0.300 12.337 2.873 (1.594–5.176) < 0.001 0.999 0.301 10.986 2.715 (1.504–4.900) 0.001
Ann Arbor stage, I–II/III–IV 15/69 0.867 0.477 3.300 2.379 (0.934–6.059) 0.069 0.975 0.526 3.436 2.650 (0.946–7.429) 0.064
Extranodal sites ≥ 2, no/yes 65/19 0.545 0.321 2.880 1.724 (0.919–3.233) 0.090 0.494 0321 2.369 1.639 (0.874–3.075) 0.124
BMB, negative/positive 63/21 0.652 0.310 4.430 1.920 (1.046–3.525) 0.035 0.624 0.310 4.050 1.866 (1.016–3.427) 0.044
Ki-67 ≥ 80%, no/yes 60/24 0.556 0.305 3.334 1.744 (0.960–3.169) 0.068 0.517 0.306 2.854 1.678 (0.920–3.057) 0.091
Platelet cell count, ≥ 150 × 109/L 48/36 0.594 0.300 3.923 1.812 (1.006–3.262) 0.048 0.588 0.300 3.836 1.800 (1.000–3.240) 0.050
IPI, 0–2/3–5 47/37 1.148 0.313 13.475 3.153 (1.708–5.820) < 0.001 1.143 0.314 13.287 3.136 (1.696–5.799) < 0.001
PIT, 0–1/2–4 41/43 1.068 0.317 11.316 2.909 (1.561–5.418) 0.001 1.113 0.324 11.799 3.044 (1.613–5.744) 0.001
IPTCLP, 0–1/2, 3 54/30 1.027 0.304 11.445 2.793 (1.540–5.064) 0.001 0.999 0.304 10.763 2.715 (1.495–4.930) 0.001
SUVmax, low/high 22/62 0.959 0.405 5.619 2.609 (1.181–5.766) 0.018 1.020 0.421 5.878 2.773 (1.216–6.325) 0.015
TMTV, low/high 43/41 1.665 0.344 23.460 5.286 (2.695–10.369) < 0.001 1.608 0.342 22.095 4.994 (2.554–9.766) < 0.001
TLG, low/high 35/49 1.201 0.351 11.680 3.324 (1.669–6.620) 0.001 1.179 0.351 11.273 3.250 (1.633–6.467) 0.001
  1. Univariate analyses of factors predictive of survival in patients whose scans were evaluated using TMTV and TLG
  2. CI confidence interval, SE standard error, LDH lactate dehydrogenase, ECOG PS Eastern Cooperative Oncology Group performance status, BMB bone marrow biopsy, IPI International Prognostic Index, PIT prognostic index for T-cell lymphoma, IPTCLP International peripheral T cell lymphoma Project, TMTV total metabolic tumor volume, TLG total lesion glycolysis
  3. *P < 0.05